United States Patent 10,799,138 (sotalol IV-to-oral with delta QTc stop rules): claim scope, coverage map, and patent landscape for US exclusivity and generic-risk

Executive summary: US 10,799,138 claims a specific clinical management method for transitioning sotalol from intravenous infusion to oral dosing based on QTc delta logic (stop IV if delta QTc is not within a defined “acceptable range,” then continue with at least one further oral dose). The independent claim is broad to “a method,” but the commercially decisive limits are the step sequence and the discontinuation criterion tied to baseline QTc and post-infusion QTc delta. Dependent claims lock in infusion dose and timing windows, renal-function–dependent maintenance intervals, and representative oral maintenance amounts. Practically, the usable “design-around” levers are (i) using a different QTc acceptability metric or threshold definition, (ii) changing the stop/transition decision structure so IV is not discontinued based on the delta QTc criterion as claimed, or (iii) altering the claimed dosing schedule details in the dependent claims.

H1: Scope and claims of US Patent 10,799,138 covering sotalol IV infusion discontinuation based on delta QTc

What is the claimed invention in one line?

A QTc-delta–driven protocol that discontinues sotalol IV infusion when delta QTc fails an “acceptable range” threshold (<20% from baseline) and then resumes with oral sotalol.

H2: What are the key claim limitations in US 10,799,138 and how do they define infringement?

Featured snippet answer: Claim 1 requires (1) baseline QTc measurement, (2) sotalol IV infusion, (3) QTc measurement after infusion, (4) calculation/comparison of delta QTc vs baseline, (5) discontinuing IV because delta QTc is not in an acceptable range of less than 20% from baseline, and (6) administering at least one further oral sotalol dose.

Claim 1 step-by-step structure (infringement-relevant ordering)

Baseline QTc detection
A “baseline QTc” must be detected before IV dosing.
IV administration of sotalol
A “dose of sotalol … via an intravenous infusion for a duration of time.”
Post-infusion QTc detection
Delta QTc determination Explicitly “determining the difference between baseline QTc and QTc measured after the intravenous infusion.”
Acceptability determination “Determining that the delta QTc is not in an acceptable range of less than 20% from the baseline QTc.” This language operationalizes a threshold: delta QTc outside “<20% from baseline.”
Discontinuation and oral continuation “Discontinuing intravenous administration … and administering at least one further dose orally.”

Enforcement consequence: Any protocol that treats IV continuation/discontinuation as a function of a different metric (different threshold, different baseline comparator, or different acceptability definition) risks avoiding claim 1. A generic manufacturer is not the direct actor; infringement targets are typically clinicians/hospitals or method-of-treatment claims asserted against those administering the regimen.

Claim 1 “acceptable range” boundary

The claim text you provided uses: “acceptable range of less than 20% from the baseline QTc.” Interpreting that as the gating rule yields two infringement poles:

In-scope: delta QTc is not within the <20% tolerance.
Out-of-scope: delta QTc is within the <20% tolerance (no IV discontinuation under this claim).

Claim 1 breadth vs dependence

Independent (broad): Method steps are relatively generic with respect to the exact infusion duration, exact IV dose, and exact oral dose amounts.
Dependent (narrow): Specific parameterizations appear in claims 2–11.

Design-around implication: Many clinical protocols use QTc monitoring and dose adjustments, but claim 1 is tethered to the specific “delta QTc not acceptable if outside <20% from baseline” rule and to the IV-to-oral transition upon discontinuation.

H2: How do claims 2–11 narrow the protocol for renal function, IV dose, infusion duration, and oral maintenance timing?

Featured snippet answer: Dependent claims specify (i) IV infusion doses (40 mg or ranges tied to renal function), (ii) infusion duration windows (0.5–2 hours), (iii) oral dose magnitudes (75/80/120/160 mg), and (iv) maintenance schedules (every 12 hours for normal renal function and every 24 hours for abnormal renal function), with representative maintenance of at least 80 mg and exemplars of 120 mg.

Dependent claim matrix (scope drivers)

Claim	Additional limitation (as provided)	Scope effect / infringement sensitivity
2	Renal function normal or abnormal; IV infusion dose is “10 mg 60 mg” (as written)	Narrows to a particular IV dose regime; also ties protocol to renal-function stratification
3	Infusion duration is 0.5 hour–2 hours	Requires matching timing window; may be a strong parameter to distinguish protocols
4	Renal function normal or abnormal; oral further dose: 75 mg, 80 mg, 120 mg, or 160 mg; oral dosing 0.5–2 hours after start of IV infusion	Narrows oral dose options and the temporal relationship between IV start and oral dosing
5	Normal renal function: maintenance oral dose ≥80 mg at 12 hours from IV initiation and every 12 hours thereafter	Anchors a 12-hour maintenance interval in normal renal function
6	Abnormal renal function: maintenance oral dose ≥80 mg at 24 hours from IV initiation and every 24 hours thereafter	Anchors a 24-hour maintenance interval in abnormal renal function
7	Claim 5 with maintenance dose = 120 mg	Narrows further to 120 mg in normal renal function
8	Claim 6 with maintenance dose = 120 mg	Narrows further to 120 mg in abnormal renal function
9	Normal renal function: maintenance oral dose once every 12 hours after IV infusion terminated	Fixes “after termination” rather than 12 hours from initiation
10	Abnormal renal function: maintenance oral dose once every 24 hours after IV infusion terminated	Fixes “after termination” rather than 24 hours from initiation
11	IV infusion dose is 40 mg sotalol	Narrows to a specific IV dose

Key internal inconsistencies to exploit for non-infringement

Claims 5–8 define timing relative to initiation of IV infusion (12 or 24 hours).
Claims 9–10 define timing relative to termination of IV infusion (every 12 or 24 hours after termination). A protocol that measures/structures dosing strictly by one reference point (initiation vs termination) may reduce overlap depending on how a court construes “from initiation” vs “after termination” and how the discontinuation step affects termination time.

Commercial relevance: Hospitals often follow renal-adjusted oral maintenance regimens. Whether their documentation ties to initiation vs termination clocks matters in method-of-use infringement.

H2: What is the likely scope of “delta QTc” logic and what protocol elements would a challenger target?

Featured snippet answer: The infringement center of gravity is the gating rule that triggers IV discontinuation when delta QTc is not within a <20% tolerance from baseline, followed by oral dosing.

What is “delta QTc” operationally?

The claim defines it as the difference between:

baseline QTc detected before IV, and
QTc measured after the IV infusion.

A challenger will focus on:

Whether the protocol uses “difference” vs ratio Claim language emphasizes “difference,” but the acceptability clause is expressed in percent (“less than 20% from baseline”). If a clinical practice uses absolute QTc change (ms) thresholds or uses a different percent formulation, it can be argued to fall outside.
How the “acceptable range” is defined The claim uses a “less than 20% from the baseline QTc” concept. Alternative acceptability rules (absolute ms threshold, Bazett vs Fridericia choice changes, or different percent bands) are likely attack points.
When QTc is measured Claim 1 requires QTc measured “after the intravenous infusion.” If the measurement timing differs materially (e.g., sampling during infusion rather than after completion), the step sequence can be contested.

What about renal-function adaptations?

Dependent claims 5–6 and 9–10 stratify maintenance interval based on renal function. A protocol that does not implement these specific interval structures may reduce dependent-claim overlap even if claim 1 remains theoretically in play.

H2: Which US patents and patent families typically surround IV-to-oral sotalol protocols, QTc monitoring, and renal-adjusted dosing?

Featured snippet answer: Without the complete bibliographic record for US 10,799,138’s full file wrapper, cited references, and related family members, a complete “count of patents” cannot be produced here.

(Per constraints: producing a numbered landscape with specific patent numbers, assignees, priority dates, and expiration dates would require sourced patent bibliographic data that is not provided in the prompt.)

H2: What is the Orange Book status of US Patent 10,799,138 and does it block generic sotalol?

Featured snippet answer: Method-of-treatment claims can be listed and can create enforcement leverage even without blocking generic product approval, but the specific Orange Book linkage for US 10,799,138 depends on whether it is listed as a patent for a specific NDA/ANDA product with sotalol dosage forms.

(Per constraints: Orange Book listing details are not provided in the prompt, so a correct determination of status and linkage cannot be generated.)

H2: When does US 10,799,138 expire and what exclusivity dates should be modeled for freedom-to-operate?

Featured snippet answer: Expiration for US patents is generally 20 years from earliest effective nonprovisional filing, subject to adjustments and terminal disclaimers, but the actual earliest priority date, PTA/PTE, and any terminal disclaimers must be taken from the patent record.

(Per constraints: priority/filing and adjustment data are not provided in the prompt, so no accurate expiration timeline can be stated.)

H2: How strong is the patent estate for sotalol QTc delta-based IV discontinuation when asserted against hospitals and clinicians?

Featured snippet answer: Strength hinges on whether clinical use in the field matches the claimed sequence and the delta-QTc threshold (<20% from baseline) and whether the measurement/discontinuation/oral transition steps are documented in a way consistent with the claim.

Practical enforcement vectors

Method-of-treatment enforcement: Suits or threats often target entities that follow the protocol, not just manufacturers.
Evidence burden: Claim 1 requires step-by-step compliance. Medical records, order sets, and clinical pathways become central exhibits.
Dependent claim leverage: If real-world protocols implement renal-based schedules and specific dose magnitudes/timing windows matching claims 2–11, the patent’s asserted coverage becomes more robust.

Litigation posture often turns on “protocol adherence”

If the accused protocol:

uses different QTc acceptability thresholds, or
does not discontinue IV administration based on delta QTc outside the claimed tolerance, or
transitions to oral in a way not satisfying “discontinuing IV… and administering at least one further dose orally,” then claim 1 becomes vulnerable on element-matching.

H2: What generic entry risks exist for sotalol based on method claims like US 10,799,138?

Featured snippet answer: Generic sotalol products may be risk-neutral on product approval but can still face method-claim allegations if prescribers administer the generic using a protocol that matches the claimed steps.

How generics can reduce risk

Avoid the delta-QTc gate language in standard protocols by adopting alternative monitoring and transition criteria.
Change oral initiation timing and maintenance interval so dependent claim parameters are not met.
Create formulary order-set differences that alter operational steps (documentation matters).

How brand can increase leverage

Promote order sets / protocols tied to QTc delta logic and the specific stop/transition criteria.
Demonstrate clinical pathway adherence across institutions using claim-1-consistent documentation.

H2: How does US 10,799,138 compare with other sotalol QT monitoring patents in the same clinical space?

Featured snippet answer: Comparison requires access to adjacent patents’ claims (monitoring metric, thresholding, and IV-to-oral transition rules) to identify overlap in delta-QTc logic, renal-adjusted schedules, and timing windows.

(Per constraints: no adjacent patent claim texts were provided, so an accurate claim-by-claim comparison cannot be completed.)

H2: What formulations and administration routes are covered, and what variants likely fall outside the claim?

Featured snippet answer: The claim requires sotalol IV infusion followed by discontinuation and oral dosing. It does not claim other routes (SC/IM) or alternative delivery systems.

Covered

sotalol IV infusion for a specified duration (dependent claim 3: 0.5–2 hours)
oral dosing after IV discontinuation (dependent claim 4: oral dose options and timing window)

Likely outside

protocols that do not include a baseline QTc and post-infusion QTc delta calculation
protocols that do not discontinue IV when delta QTc is outside a <20% baseline tolerance
protocols that maintain IV dosing regardless of delta QTc and only adjust oral dosing
protocols that use a different QTc acceptability methodology (absolute ms threshold only, different percent construct, or a different baseline comparator)

H2: What litigation and settlement outcomes typically matter for this kind of US method claim?

Featured snippet answer: The most probative outcomes are those resolving claim construction for “delta QTc,” the acceptability threshold (“less than 20%”), and the element “discontinuing intravenous administration.”

(Per constraints: litigation status, specific case captions, court dockets, and settlement terms are not provided.)

H2: Key dates and “infringement windows” for real-world administration

Featured snippet answer: The operational window is the period from (i) baseline QTc measurement through (ii) post-infusion QTc measurement and IV discontinuation, then (iii) oral dose initiation and maintenance scheduling.

Time architecture implied by the dependent claims

Infusion duration: 0.5 to 2 hours (claim 3)
Oral dosing after IV start: 0.5 to 2 hours after start (claim 4)
Maintenance intervals:
- normal renal function: every 12 hours (claims 5 and 9)
- abnormal renal function: every 24 hours (claims 6 and 10)

Key Takeaways

US 10,799,138 claim 1 is centered on a QTc delta trigger that requires discontinuing sotalol IV when delta QTc is outside a <20% tolerance vs baseline and then continuing with oral dosing.
Dependent claims add operational specificity: infusion duration (0.5–2 hours), representative IV and oral dose values, and renal-function–linked maintenance schedules (12-hour vs 24-hour interval structures).
Infringement risk is primarily a function of whether clinical pathways and documentation match the precise sequence and the specific delta-QTc acceptability threshold.
Design-arounds typically target (i) the delta-QTc threshold definition, (ii) the decision logic for discontinuing IV, and/or (iii) the timing reference point and scheduling details used for maintenance dosing.

FAQs

Can a protocol still infringe if clinicians measure QTc using a different correction formula (Bazett vs Fridericia) even when “delta” is computed?
If IV infusion is stopped for reasons other than delta QTc acceptability, does the claim still apply when oral dosing occurs?
How do initiation-based (12/24 hours from IV start) versus termination-based (every 12/24 hours after IV ends) dosing schedules affect claim coverage?
Does the claim cover only transitions from IV to oral, or can partial oral dosing during infusion satisfy “after discontinuing IV”?
What clinical documentation elements typically determine whether the “baseline QTc,” “after infusion QTc,” and “delta QTc” steps are proven for method claim enforcement?

References

No sources were provided in the prompt, and no external patent bibliographic or regulatory data was cited.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Altathera Pharms Llc	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	SOLUTION;INTRAVENOUS	022306-001	Jul 2, 2009		RX	Yes	Yes	10,799,138	⤷ Start Trial				INTRAVENOUS SOTALOL DOSING REGIMEN FOR USE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING	⤷ Start Trial
Altathera Pharms Llc	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	SOLUTION;INTRAVENOUS	022306-001	Jul 2, 2009		RX	Yes	Yes	10,799,138	⤷ Start Trial				USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,799,138

Which drugs does patent 10,799,138 protect, and when does it expire?

Summary for Patent: 10,799,138